EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia

Husain Attarwala, Matthew Lumley, Min Liang, Vijay Ivaturi, Joe Senn

Nucleic Acid Therapeutics · 01.04.2023 · 33 (2) · 141-147

DOI: 10.1089/nat.2022.0036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 30.03.2023. Verfasst von Husain Attarwala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Moderna, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Propionic Acidemia. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Propionic acidemia (PA) is an ultrarare disorder caused by deficiency of the mitochondrial enzyme, propionyl-CoA carboxylase (PCC), composed of PCCA and PCCB subunits. An enzyme replacement therapy is being developed using dual messenger RNA (mRNA) therapy composed of lipid nanoparticles (LNPs) encapsulating mRNAs encoding PCCA and PCCB subunits of the PCC enzyme. We herein report on development of a translational semimechanistic pharmacokinetic (PK) and PK/pharmacodynamic (PD) model to quantify the relationship between the mRNA components of mRNA-3927 (an LNP encapsulating PCCA and PCCB mRNAs) and dose levels; PCCA/B mRNA PK and PD responses were assessed as circulating levels of primary disease markers 2-methyl citrate, 3-hydroxypropionate, and propionyl carnitine normalized to acetyl carnitine (C3/C2 ratio) to inform the first-in-human dose range and regimen selection. The translational PK/PD model was developed using preclinical data available in mice with PA, Sprague Dawley rats, and cynomolgus monkeys at dose levels ranging from 0.2 to 9 mg/kg. PCCA/B mRNA PK in mice, rats, and monkeys was adequately described using allometric scaling of volume and clearance parameters. The interspecies preclinical model was scaled allometrically to humans to predict the dose–response relationship in adult and pediatric patients with PA to guide selection of dose range and regimen for the Phase 1 clinical trial ( ClinicalTrials.gov Identifier NCT04159103).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Propionic AcidemiaAdultHumansChildMiceRatsAnimalsMutationRNA, MessengerRats, Sprague-DawleyMethylmalonyl-CoA Decarboxylase

Stichwörter der Autor:innen

lipid nanoparticlesmRNA therapypropionic acidemiapropionyl-CoA carboxylase

Substanzen

RNA, MessengerMethylmalonyl-CoA Decarboxylase

Autor:innen und Institutionen

  • Moderna, Inc., Cambridge, Massachusetts, USA.
  • Pumas AI, Inc., Centreville, Virginia, USA.

Zitieren

APA

Attarwala, H., Lumley, M., Liang, M., Ivaturi, V., & Senn, J. (2023). Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia. Nucleic Acid Therapeutics, 33(2), 141-147. https://doi.org/10.1089/nat.2022.0036

Vancouver

Attarwala H, Lumley M, Liang M, Ivaturi V, Senn J. Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia. Nucleic Acid Therapeutics. 2023;33(2):141-147. doi:10.1089/nat.2022.0036

BibTeX
@article{Attarwala2023,
  author = {Attarwala, Husain and Lumley, Matthew and Liang, Min and Ivaturi, Vijay and Senn, Joe},
  title = {Translational Pharmacokinetic/Pharmacodynamic Model for mRNA-3927, an Investigational Therapeutic for the Treatment of Propionic Acidemia},
  journal = {Nucleic Acid Therapeutics},
  year = {2023},
  volume = {33},
  number = {2},
  pages = {141--147},
  doi = {10.1089/nat.2022.0036}
}
Kostenlos starten →